MNG
BMRN icon

Manning & Napier Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Manning & Napier Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$101M Buy
1,153,785
+8,672
+0.8% +$776K 1.15% 29
2023
Q4 		$110M Buy
1,145,113
+6,161
+0.5% +$545K 1.31% 21
2023
Q3 		$101M Buy
1,138,952
+1,193
+0.1% +$106K 1.25% 22
2023
Q2 		$98.6M Buy
1,137,759
+37,041
+3% +$3.49M 1.13% 28
2023
Q1 		$107M Buy
1,100,718
+226,152
+26% +$23.4M 1.25% 21
2022
Q4 		$90.5M Sell
874,566
-57,225
-6% -$5.37M 1.11% 23
2022
Q3 		$79M Sell
931,791
-14,610
-2% -$1.3M 1.03% 24
2022
Q2 		$78.4M Sell
946,401
-758,954
-45% -$60.4M 0.91% 35
2022
Q1 		$131M Sell
1,705,355
-31,704
-2% -$2.65M 1.25% 24
2021
Q4 		$153M Sell
1,737,059
-5,922
-0.3% -$489K 1.28% 22
2021
Q3 		$135M Buy
1,742,981
+15,597
+0.9% +$1.23M 1.16% 27
2021
Q2 		$144M Buy
1,727,384
+22,542
+1% +$1.79M 1.18% 22
2021
Q1 		$129M Buy
1,704,842
+621,482
+57% +$50.8M 1.09% 23
2020
Q4 		$95M Sell
1,083,360
-49,358
-4% -$3.91M 0.88% 35
2020
Q3 		$86.2M Buy
1,132,718
+162,195
+17% +$16.4M 0.87% 34
2020
Q2 		$120M Sell
970,523
-79,835
-8% -$7.93M 1.28% 24
2020
Q1 		$88.8M Sell
1,050,358
-49,833
-5% -$4.29M 1.05% 32
2019
Q4 		$93M Buy
1,100,191
+370,098
+51% +$28M 1% 29
2019
Q3 		$49.2M Buy
730,093
+4,032
+0.6% +$311K 0.55% 48
2019
Q2 		$62.2M Sell
726,061
-184,898
-20% -$15.8M 0.68% 42
2019
Q1 		$80.9M Sell
910,959
-88,959
-9% -$8.24M 0.89% 32
2018
Q4 		$85.1M Sell
999,918
-404,610
-29% -$38.5M 1.04% 32
2018
Q3 		$136M Sell
1,404,528
-479,145
-25% -$47.8M 1.34% 19
2018
Q2 		$177M Sell
1,883,673
-32,785
-2% -$2.87M 1.75% 17
2018
Q1 		$155M Sell
1,916,458
-64,419
-3% -$5.53M 1.52% 21
2017
Q4 		$177M Buy
+1,980,877
New +$172M 1.59% 16

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Manning & Napier Group's BMRN Position: Q1 2024 in Review

Manning & Napier Group increased its BioMarin Pharmaceuticals (BMRN) stake by 0.76% in Q1 2024, buying an estimated $776K and bringing the position to 1,153,785 shares worth $101M. The position accounts for 1.15% of the portfolio, ranked #29.

Manning & Napier Group first reported a position in BMRN in Q4 2017 and has held it in 26 quarters since. The position peaked at $177M in Q2 2018. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Manning & Napier Group held 1,153,785 shares of BioMarin Pharmaceuticals worth $101M as of Q1 2024.
  • Manning & Napier Group bought 8,672 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $776K.
  • BioMarin Pharmaceuticals made up 1.15% of Manning & Napier Group's portfolio in Q1 2024, its #29 holding.
  • Manning & Napier Group first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 26 quarters since.
  • Manning & Napier Group's BioMarin Pharmaceuticals position peaked at $177M in Q2 2018.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Manning & Napier Group's 13F filing for Q1 2024, filed 15 Apr 2024.